Girls included in the immunogenicity subset in the primary controlled, observer-blinded, randomized study (“type”:”clinical-trial”,”attrs”:”text”:”NCT00196924″,”term_id”:”NCT00196924″NCT00196924) who received 3 doses were invited for a 10-year follow-up (“type”:”clinical-trial”,”attrs”:”text”:”NCT00316706″,”term_id”:”NCT00316706″NCT00316706 and “type”:”clinical-trial”,”attrs”:”text”:”NCT00877877″,”term_id”:”NCT00877877″NCT00877877). 50 years for anti-HPV-16 and anti-HPV-18. For the non-vaccine humoral type response, all initially seronegative subjects had seroconverted at M7, with anti-HPV-31 GMT of 2030.5 EU/mL (95% CI: 1766.2C2334.4) and anti-HPV-45 GMT of 2300.8 EU/mL (95% CI: 2036.8C2599.0). At M120, 87.7% and 85.1% remained seropositive for anti-HPV-31 with GMT of 242.9 EU/mL (95% CI: 201.4C293.0) and anti-HPV-45 with GMT of 204.7 EU/mL (95% CI: 170.0C246.6). During the 10-year follow-up, no SAEs or abnormal pregnancy outcomes were causally related to vaccination. Three doses of the AS04-HPV-16/18 vaccine induced high and sustained antibody response against HPV-16,18,31 and Calcifediol-D6 45 in Calcifediol-D6 girls aged 10C14 years during the 10-year follow-up, with an acceptable long-term Mouse monoclonal to CD14.4AW4 reacts with CD14, a 53-55 kDa molecule. CD14 is a human high affinity cell-surface receptor for complexes of lipopolysaccharide (LPS-endotoxin) and serum LPS-binding protein (LPB). CD14 antigen has a strong presence on the surface of monocytes/macrophages, is weakly expressed on granulocytes, but not expressed by myeloid progenitor cells. CD14 functions as a receptor for endotoxin; when the monocytes become activated they release cytokines such as TNF, and up-regulate cell surface molecules including adhesion molecules.This clone is cross reactive with non-human primate safety profile. KEYWORDS: HPV-16/18 AS04-adjuvanted vaccine, HPV-31, HPV-45, non-vaccine types, cross-reactivity, immunogenicity persistence, safety, predictive modeling Introduction Cervical cancer is one of the leading causes of female cancer worldwide.1 Persistent oncogenic human papillomavirus (HPV) infection is necessary for developing cervical cancer.2 At least 13 oncogenic types of HPV have been identified; among them, HPV-16 and HPV-18 cumulatively account for approximately 70% of cervical cancer cases.3 Other oncogenic types include HPV-45 and HPV-31 that account together for an additional 8.5% of all cervical cancer cases worldwide.1 The risk of cervical HPV infection starts soon after sexual debut;4 and the risk of HPV contamination persists throughout the active sexual life of women.5 Therefore, an HPV vaccine that induces a sustained immune response and provides long-term protection is of paramount importance for an HPV vaccination program that targets young girls before sexual debut.6C8 The AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18, analysis around the humoral response against the non-vaccine type HPV-31 and HPV-45, 150 subjects with residual serum volume greater than 300 L were randomly selected from the ATP cohort. Serum antibody response against HPV-16 and HPV-18 Among the 418 subjects who were included in the ATP immunogenicity cohort, anti-HPV-16 antibody data and anti-HPV-18 antibody data were available for 416 and 415 subjects, respectively. At the baseline, 393 (94.5%) out of the 416 subjects were seronegative for anti-HPV-16 antibodies and 395 (95.2%) out of the 415 subjects were seronegative for anti-HPV-18 antibodies. At Month 120 post vaccination, all subjects who were included in the ATP immunogenicity cohort were still seropositive for anti-HPV-16 and anti-HPV-18 antibodies. The geometric mean titer (GMT) values at Month 120 of initially seronegative subjects were 1,589.9 enzyme-linked immunosorbent assay unit [EU]/mL (95% confidence interval [CI]: 1,459.8C1,731.6) for HPV-16 and 597.2 EU/mL (95% CI: 541.7C658.5) for HPV-18. The GMT values at Month 120 of initially seropositive subjects were 1,950.1 EU/mL (95% CI: 1,416.9C2,683.8) for HPV-16 and 866.0 EU/mL (95% CI: 533.4C1,406.1) for HPV-18. The Month 120 antibody GMTs between the initially seronegative and seropositive subjects were Calcifediol-D6 not significantly different as the 95% CIs were largely overlapping for both anti-HPV-16 and -18. The HPV-16 and HPV-18 antibody titers at Month 120 were 53.4-fold [95% CI: 47.4C60.1] and 26.3-fold [95% CI: 23.6C29.4] higher, respectively, than those observed after natural infection in subjects 15C25 years of Calcifediol-D6 age (“type”:”clinical-trial”,”attrs”:”text”:”NCT00122681″,”term_id”:”NCT00122681″NCT00122681) (Determine 2).21 The HPV-16 and HPV-18 antibody titers at Month 120 were 3.8-fold [95% CI: 3.1C4.6] and 2.5-fold [95% CI: 2.0C3.1] higher, respectively, than those measured 9.4 years after vaccination Calcifediol-D6 in subjects vaccinated at the ages of 15C25 years (“type”:”clinical-trial”,”attrs”:”text”:”NCT00518336″,”term_id”:”NCT00518336″NCT00518336)(Figure 2).15 Open in a separate window Determine 2. GMTs for anti-HPV-16 and anti-HPV-18 antibodies in initially seronegative subjects (Month 120 ATP immunogenicity cohort)..